<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05014698</url>
  </required_header>
  <id_info>
    <org_study_id>RC19_0414</org_study_id>
    <nct_id>NCT05014698</nct_id>
  </id_info>
  <brief_title>IDEntification of New Predisposition Genes in Differentiated THYroid Cancer</brief_title>
  <acronym>IDENTHY-K</acronym>
  <official_title>IDEntification of New Predisposition Genes in Differentiated THYroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to find new predisposition genes for differentiated thyroid&#xD;
      cancer (DTC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research is to find new predisposition genes for differentiated thyroid&#xD;
      cancer (DTC). Therefore, in the absence of a BAP1 and DICER1 abnormality, we offer to&#xD;
      sequence your whole genome (WGS) or partial genome (genotyping) for a previously unknown&#xD;
      genetic abnormality.&#xD;
&#xD;
      Furthermore, the discovery of new genes would be a major medical advance that could&#xD;
      contribute to the identification of new therapeutic targets.&#xD;
&#xD;
      This research will be conducted at the University Hospital of Nantes and the Hospital of&#xD;
      Vendée and 95 people should participate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Type and Number of genetic variants associated with or causing the development of differentiated thyroid cancer</measure>
    <time_frame>within 2 years</time_frame>
    <description>To be achieved by a whole genome sequencing (WGS) approach in a familial analysis of patients with differentiated thyroid cancer. In addition, high-throughput genotyping of multiple individuals in each family will allow complementary detection of genomic regions that are shared only by affected subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of phenotypes associated to genotypes of CDT</measure>
    <time_frame>within 2 years</time_frame>
    <description>By studying the association between the clinical characteristics of patients and the identified genetic variants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of birthplace/family origin information</measure>
    <time_frame>within 2 years</time_frame>
    <description>Definition of the spatial location of family forms of CDT and to identify possible founding effects</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">95</enrollment>
  <condition>Differentiated Thyroid Cancer</condition>
  <condition>Thyroid Cancer, Nonmedullary</condition>
  <arm_group>
    <arm_group_label>WGS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>at inclusion visit :&#xD;
- Blood collection for whole Genome sequencing will be performed&#xD;
At final visit :&#xD;
the results of the WGS will be delivered to patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>WGS</intervention_name>
    <description>Whole Genome sequencing</description>
    <arm_group_label>WGS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Probant subjects&#xD;
&#xD;
          -  Minor or adult subject&#xD;
&#xD;
          -  Adult subject or legal guardian for minor subjects agreeing to sign the study consent&#xD;
             and biospecimen consent&#xD;
&#xD;
          -  Subject with differentiated thyroid cancer without an identified causative mutation in&#xD;
             the BAP1 and DICER 1 predisposition genes&#xD;
&#xD;
          -  Patient affiliated to a valid social security plan&#xD;
&#xD;
        Relative subjects&#xD;
&#xD;
          -  Adult subjects&#xD;
&#xD;
          -  Subject agreeing to sign the study consent and the biocollection consent&#xD;
&#xD;
          -  Subject with differentiated thyroid cancer or from a family with several cases of&#xD;
             differentiated thyroid cancer without a causal mutation identified in the BAP1 and&#xD;
             DICER 1 predisposition genes&#xD;
&#xD;
          -  Patient affiliated to a social security plan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject refusing to participate&#xD;
&#xD;
          -  Subjects with a causal mutation identified in the predisposition genes: BAP1 and DICER&#xD;
             1&#xD;
&#xD;
          -  Subjects under guardianship, curatorship or safeguard of justice or not socially&#xD;
             insured&#xD;
&#xD;
          -  Subjects with another syndromic predisposition to thyroid cancer (Cowden, Werner, PAF)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vendée Hospital</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Bernardette LUCAS-POULIQUEN, MD</last_name>
      <email>bernadette.lucas-pouliquen@ght85.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Delphine DRUI, MD</last_name>
      <email>delphine.drui@chu-nantes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Matthieu PICHELIN, PhD</last_name>
      <email>Matthieu.Pichelin@univ-nantes.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

